Corbus Pharmaceuticals Holdings, Inc. Stock
Equities
CRBP
US21833P3010
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
35.79 USD | -5.17% | -2.64% | +499.02% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 397M |
---|---|---|---|---|---|
Net income 2024 * | -53M | Net income 2025 * | -65M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.25
x | P/E ratio 2025 * |
-7.37
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.31% |
Latest transcript on Corbus Pharmaceuticals Holdings, Inc.
1 day | +0.11% | ||
1 week | -8.22% | ||
Current month | -3.82% | ||
1 month | +8.01% | ||
3 months | +416.99% | ||
6 months | +551.81% | ||
Current year | +524.83% |
Managers | Title | Age | Since |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 14-04-10 |
Chief Tech/Sci/R&D Officer | 50 | Feb. 27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 13-12-31 |
Avery Catlin
BRD | Director/Board Member | 75 | 14-07-31 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 36.24 | -3.97% | 76 588 |
24-04-23 | 37.74 | +0.11% | 500,521 |
24-04-22 | 37.7 | -3.92% | 94,730 |
24-04-19 | 39.24 | +7.42% | 283,601 |
24-04-18 | 36.53 | -1.70% | 128,065 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+524.83% | 397M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+2.04% | 22.19B | |
-16.16% | 21.33B | |
-6.82% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- CRBP Stock